Literature DB >> 19837293

Technical transformation of biodefense vaccines.

Shan Lu1, Shixia Wang.   

Abstract

Biodefense vaccines are developed against a diverse group of pathogens. Vaccines were developed for some of these pathogens a long time ago but they are facing new challenges to move beyond the old manufacturing technologies. New vaccines to be developed against other pathogens have to determine whether to follow traditional vaccination strategies or to seek new approaches. Advances in basic immunology and recombinant DNA technology have fundamentally transformed the process of formulating a vaccine concept, optimizing protective antigens, and selecting the most effective vaccine delivery approach for candidate biodefense vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837293      PMCID: PMC3729025          DOI: 10.1016/j.vaccine.2009.08.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  140 in total

1.  Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Authors:  C S Schmaljohn; M D Parker; W H Ennis; J M Dalrymple; M S Collett; J A Suzich; A L Schmaljohn
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

2.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

3.  Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates.

Authors:  Jay W Hooper; David M Custer; Jeffrey Smith; Victoria Wahl-Jensen
Journal:  Virology       Date:  2005-12-27       Impact factor: 3.616

Review 4.  Prospects for improved bluetongue vaccines.

Authors:  Polly Roy; Mark Boyce; Robert Noad
Journal:  Nat Rev Microbiol       Date:  2009-02       Impact factor: 60.633

5.  Immunologic response of sheep to inactivated and virulent bluetongue virus.

Authors:  J L Stott; T L Barber; B I Osburn
Journal:  Am J Vet Res       Date:  1985-05       Impact factor: 1.156

Review 6.  Molecular basis for improved anthrax vaccines.

Authors:  Robert N Brey
Journal:  Adv Drug Deliv Rev       Date:  2005-04-21       Impact factor: 15.470

7.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

8.  Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants.

Authors:  M Hevey; D Negley; J Geisbert; P Jahrling; A Schmaljohn
Journal:  Virology       Date:  1997-12-08       Impact factor: 3.616

9.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

10.  A novel, killed-virus nasal vaccinia virus vaccine.

Authors:  Anna U Bielinska; Alexander A Chepurnov; Jeffrey J Landers; Katarzyna W Janczak; Tatiana S Chepurnova; Gary D Luker; James R Baker
Journal:  Clin Vaccine Immunol       Date:  2007-12-05
View more
  1 in total

1.  The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge.

Authors:  Dina R Weilhammer; Craig D Blanchette; Nicholas O Fischer; Shabnam Alam; Gabriela G Loots; Michele Corzett; Cynthia Thomas; Cheri Lychak; Alexis D Dunkle; Joyce J Ruitenberg; Smita A Ghanekar; Andrea J Sant; Amy Rasley
Journal:  Biomaterials       Date:  2013-09-27       Impact factor: 12.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.